John Sweetenham, MD, PhD

Editorials by John Sweetenham, MD

EditorialPublication Exclusive

The end(point) game in indolent lymphoma: After years-long search, data suggest genuine progress

HemOnc Today, September 10, 2015
John Sweetenham, MD
Evidence from several sources suggests that OS for patients with follicular lymphoma has improved in recent years. The reasons for this improvement…
EditorialPublication Exclusive

Research reveals fine line between ‘one more try’ and ‘a bridge too far’

HemOnc Today, August 25
John Sweetenham, MD
“I think we may be going a bridge too far.”  – Lt. Gen. Frederick Browning, prior to the First Allied Airborne Army’s…
EditorialPublication Exclusive

Drug cost debate must not detract from focus on value in cancer care

HemOnc Today, July 10, 2015
John Sweetenham, MD
We are all at various stages of readiness for the transition from volume-based to value-based care. The development of value-based care models is a…
EditorialPublication Exclusive

Liquid biopsies offer ‘transformative’ potential for detection of aggressive lymphomas

HemOnc Today, June 10, 2015
John Sweetenham, MD
This issue of HemOnc Today includes an article that describes a study from the NCI that investigated the use of circulating tumor DNA as a tumor…
EditorialPublication Exclusive

Small molecules, ‘big data’ and the EMR

HemOnc Today, May 10, 2015
John Sweetenham, MD
It’s strange how apparently unrelated events sometimes seem to converge into a common theme. During the past couple weeks, I attended a preview of —…
EditorialPublication Exclusive

AICR report reveals new angle on ‘mismatch repair’ in cancer

HemOnc Today, March 10, 2015
John Sweetenham, MD
The World Health Organization designated Feb. 4 as World Cancer Day. I know this only because I happened to see it mentioned on Twitter. Otherwise, I…
EditorialPublication Exclusive

Déjà vu all over again — or am I missing the take-home message?

HemOnc Today, February 10, 2015
John Sweetenham, MD
In my clinic recently, I saw a vigorously healthy 79-year-old woman newly diagnosed with diffuse large B-cell lymphoma. She has virtually no…
EditorialPublication Exclusive

Robust data needed to settle maintenance therapy debate in hematologic malignancies

HemOnc Today, January 10, 2015
John Sweetenham, MD
The value of post-induction maintenance therapy in hematologic malignancies has gained renewed attention over the last few years. For the most part…
EditorialPublication Exclusive

A new angle on ‘patient experience’ in oncology: The challenge of patient-reported outcomes

HemOnc Today, December 10, 2014
John Sweetenham, MD
“Listen to your patient, he is telling you the diagnosis.”
— Sir William Osler
EditorialPublication Exclusive

Data-based medicine: When data and ‘opinion’ collide

HemOnc Today, November 25, 2014
John Sweetenham, MD
As a hematology/oncology fellow, I was fortunate enough to have a remarkable medical oncologist, Ben Mead, FRCR, FRCP, as a mentor. His approach to…